Haleon PLC Advances Oral Care Innovation with Denture Adhesive Effectiveness Study

Haleon PLC (GB:HLN) announced an update on their ongoing clinical study.

Haleon PLC (GB:HLN) is conducting a decentralised, real-world study titled “A Decentralised, Open-labelled, Clinical Study to Assess the Effectiveness of a Marketed Denture Adhesive in Food Occlusion in Denture Wearers.” The study aims to evaluate the effectiveness of Poligrip Power Max Hold + Seal denture adhesive cream in preventing food entrapment under dentures, as self-assessed by participants during two three-week observation periods—one without adhesive and one using the product.

The intervention being tested is Poligrip Power Max Hold + Seal, a marketed denture adhesive cream intended to improve food occlusion and comfort for denture wearers. Its formulation includes sodium-calcium mixed partial salt of poly(methylvinylether/maleic acid) and carboxymethylcellulose, designed for daily use.

This interventional study employs a single-group design without masking. Participants alternate between wearing dentures without adhesive in the first phase and with the adhesive in the second phase to compare results. The primary purpose is categorized as “Other,” focusing on real-world product effectiveness.

Recruitment began on November 28, 2025, with a recent update submitted on December 15, 2025. The primary completion and estimated final study completion dates are not yet provided, implying ongoing progress and data collection.

If successful, this study could strengthen Haleon’s position in the oral care market, boosting investor sentiment and stock performance. With Poligrip holding a large share in the denture adhesive segment, this research may address consumer needs and validate product reliability amidst competition in the dental care industry.

The study remains active, with updates available on the ClinicalTrials portal.

To learn more about GB:HLN’s potential, visit the Haleon PLC drug pipeline page.